Italia markets open in 32 minutes

Cellectis S.A. (0WA2.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
2,6500-0,0680 (-2,50%)
Alla chiusura: 04:40PM GMT
Schermo intero
Chiusura precedente2,7180
Aperto2,6542
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno2,3514 - 2,4300
Intervallo di 52 settimane2,3514 - 2,4300
Volume3.740
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,85
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information

    NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, in accordance with French regulatory requirements, is supplementing its previous announcement of the pricing of its underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (“ADS”), each representin

  • GlobeNewswire

    Cellectis Announces Pricing of Follow-On Offering

    NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces the pricing of its previously announced underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (“ADS”), each representing the right to receive one ordinary share of Cellectis, nominal va

  • GlobeNewswire

    Cellectis Announces Launch of Follow-On Offering

    NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the launch of a global offering of USD 22 million of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis, nominal value €0.05 per share (the “Global Offering”) pursuant to an underwriti